Can Proteomics Predict Disease Before Symptoms Appear?

Early Disease Signals in the Proteome
Key Technologies in Proteomics
From Discovery to Validation
Where Proteomics is Gaining Ground
Translating Proteomics into Clinical Practice
The Road to Routine Proteomics
References and Further Reading

Detecting disease before symptoms appear has long been a central goal of preventive medicine. The earlier a condition can be identified, the greater the opportunity to intervene before significant damage occurs. Advances in genomics have pushed this effort forward, enabling researchers to assess disease risk based on inherited and somatic genetic variation. Yet genetics alone cannot fully reflect the complex biological changes that unfold as disease begins to develop.

This is where proteomics is beginning to play an important role. While the genome provides a blueprint, proteins represent the active machinery of the cell, carrying out the biological processes that ultimately shape health and disease. Because protein expression and activity respond to environmental factors, ageing, and ongoing physiological changes, the proteome can offer a more immediate view of emerging pathology.

In recent years, improvements in large-scale proteomic analysis have made it increasingly possible to identify early biological signals that appear before clinical symptoms are visible. Understanding these signals could help refine risk prediction and open the door to earlier intervention.

This article examines how proteomics is being applied to pre-symptomatic disease detection, reviews the technologies enabling these advances, and considers the challenges that still need to be addressed before these approaches become part of routine clinical care.

Save this PDF for later by downloading it here.

Early Disease Signals in the Proteome

Proteins sit at the center of biological activity. While the genome provides a relatively stable record of inherited information, the proteome reflects what is happening in the body at a given moment. Protein levels and behavior shift in response to gene expression, environmental exposures, aging, and disease processes. As a result, changes in protein abundance, structure, localization, post-translational modifications (PTMs), or interaction networks can appear well before clear clinical symptoms emerge.¹

Because proteins operate within interconnected biological pathways, proteomic data also captures signals from multiple processes at once. Rather than reflecting a single genetic variant or isolated molecular event, protein patterns can reveal how different biological systems respond collectively to stress, damage, or early pathological changes. This broader perspective can expose early indicators of disease that may not be visible through genomic analysis alone.¹

In many cases, disruptions in protein networks occur during the earliest stages of disease development. Detecting these shifts provides a biologically grounded way to identify pathology before symptoms become apparent, offering opportunities for earlier risk assessment and more timely intervention.¹

Key Technologies in Proteomics

Recent advances in analytical technologies have significantly expanded the feasibility of predictive proteomics. Improvements in sensitivity, proteome coverage, and scalability now allow researchers to profile protein patterns across large cohorts with increasing precision.

A key contributor is high-resolution mass spectrometry (MS). Improvements in instrument sensitivity, dynamic range, and quantitative accuracy now support the detection of low-abundance proteins that may serve as early biomarkers, and modern innovations such as data-independent acquisition (DIA) and enhanced ion mobility have boosted proteome coverage and throughput.²

In addition to optimized sample preparation workflows, including automated digestion and high-pH reversed-phase fractionation, such strategies have reduced missing data and improved reproducibility across large-scale studies, while refined approaches in plasma studies further enhance detection of scarce proteomic signals, strengthening early disease signal capture.³

In parallel, affinity-based platforms, including those developed by SomaLogic and Olink, have expanded the scalability of proteomic profiling. Technologies developed by companies such as SomaLogic and Olink allow simultaneous quantification of large protein panels from small sample volumes using aptamer- or antibody-based assays. These platforms have made it possible to conduct proteomic analyses across biobank-scale populations involving tens of thousands of participants.⁴

As datasets from these studies grow larger and more complex, computational analysis has become increasingly important. Machine learning (ML) and artificial intelligence (AI) approaches help identify predictive protein patterns, improve signal detection, and integrate proteomic data with genomic, transcriptomic, metabolomic, and clinical information. More recently, deep learning–based algorithms have also improved the analysis of complex DIA datasets, further strengthening the analytical capabilities of large-scale proteomic studies.⁵

From Discovery to Validation

Identifying potential biomarkers is only the first step. Translating proteomic discoveries into clinically useful tests has historically been one of the most difficult stages of biomarker research.⁶ Many promising signals identified in early studies fail to hold up when tested across larger or more diverse populations. 

In response, researchers have begun to place greater emphasis on more rigorous validation strategies. Replicating findings across multiple cohorts, confirming results in independent populations, and comparing new biomarkers with established clinical risk models have all become increasingly important steps in the development process.⁷ These measures help determine whether a protein signature provides meaningful predictive value beyond existing diagnostic tools.

At the same time, the development of regulatory-grade assays is receiving greater attention. Analytical validation now commonly includes assessments of reproducibility, sensitivity, and robustness across laboratories. This is particularly important for multi-protein panels intended to guide clinical decision-making, where consistency and reliability are essential.⁶

Applying a multi-omics approach has further strengthened the predictive performance of proteomic models. By capturing the combined effects of multiple biological layers, this approach often yields higher accuracy than any single modality alone.⁸

Ultimately, the success of predictive proteomics will depend not only on statistical performance but also on clear evidence of clinical utility. Protein signatures must demonstrate that they improve risk prediction beyond current models and provide information that can meaningfully guide preventive strategies or therapeutic decisions.¹

Where Proteomics is Gaining Ground

Progress in predictive proteomics varies across disease areas, with several domains showing particularly strong early evidence.

Cardiovascular disease has been a leading focus. Large cohort analyses have identified circulating protein signatures that predict incident myocardial infarction (MI), stroke, and heart failure years before occurrence, even after adjusting for traditional risk factors.⁹ Because cardiovascular pathology develops gradually, proteomic changes can precede clinical events, offering opportunities for early risk stratification. Proteomic models in MI survivors have also highlighted proteins associated with adverse cardiovascular outcomes.¹⁰

Oncology is another active area. Researchers are exploring circulating tumor-derived proteins and immune response markers as potential tools for early cancer detection, particularly when combined with imaging or other biomarkers. For example, proteomic profiling studies have reported preliminary protein signatures capable of distinguishing early-stage lung cancer from high-risk control groups. At the same time, targeted MS-based approaches continue to identify multi-analyte panels that may support future cancer biomarker development.¹¹

Neurodegenerative diseases, including Alzheimer- and Parkinson-related pathology, have also emerged as an important focus for predictive proteomics. These disorders are associated with changes in proteins linked to neuronal injury, synaptic dysfunction, and glial activation. Large-scale plasma proteomics studies have identified preclinical protein signatures that can appear years before a formal diagnosis, raising the possibility of earlier detection during the silent stages of disease progression.¹²

Metabolic diseases, including type 2 diabetes, provide another example. They have demonstrated predictive proteomic signatures. Plasma proteomic scores modestly improve the prediction of diabetes and related traits beyond conventional risk factors, and shared protein signatures can also predict coronary heart disease incidence in affected individuals.¹³

Translating Proteomics into Clinical Practice

Despite its promise, the predictive performance of proteomics is not consistent across all diseases or study designs. While many protein signatures show statistically significant associations with disease risk, their ability to improve prediction beyond established clinical models is often modest. In some cases, advanced computational models also show variable calibration and generalizability when applied to different populations or disease endpoints.^14,15

Beyond predictive performance, practical and logistical challenges continue to slow the broader clinical adoption of proteomics. Analytical variability, pre-analytical factors, and platform-specific biases can influence results, highlighting the need for standardized sample handling procedures, assay protocols, and cross-platform benchmarking.^16,17

Cost and scalability present additional hurdles. Although proteomic technologies have become more powerful and accessible, large-scale implementation in clinical settings still requires affordable, high-throughput workflows and clear reporting frameworks that translate complex molecular data into clinically meaningful outputs.

There are also important ethical and healthcare system considerations. Identifying individuals at elevated risk before symptoms appear raises questions about follow-up testing, the possibility of overdiagnosis, psychological impacts on patients, reimbursement structures, and long-term data governance.¹⁸ These factors complicate the path from research discovery to routine clinical use.

Longitudinal evidence linking proteomic changes directly to clinical outcomes is still developing, emphasizing the need for predictive models that remain robust across populations and over time.¹⁹ At the same time, regulatory frameworks are evolving to address increasingly complex biomarker panels and analytical approaches. Together, these challenges highlight that successful clinical translation will depend not only on technological advances but also on rigorous validation, regulatory clarity, and carefully designed prospective studies that demonstrate improvements in patient care.¹

The Road to Routine Proteomics

Proteomics is expanding the ability to detect biological change during clinically silent phases of disease. Advances in large-scale datasets, analytical platforms, and computational modeling have moved the field from conceptual promise toward structured real-world evaluation. Future progress will depend less on technological capability and more on disciplined implementation, including consistent performance across populations and integration into clinical workflows.

As healthcare evolves in the era of precision medicine, the long-term impact of proteomics will depend on its ability to translate complex molecular signals into clinically actionable insight while meeting the evidentiary standards required for responsible adoption.

References and Further Reading

1. You, J., Guo, Y., Zhang, Y., Kang, J.-J., Wang, L.-B., Feng, J.-F., Cheng, W., & Yu, J.-T. (2023). Plasma proteomic profiles predict individual future health risk. Nature Communications, 14, 7817. DOI:10.1038/s41467-023-43575-7, https://www.nature.com/articles/s41467-023-43575-7
2. Yarbro, J. M., Shrestha, H. K., Wang, Z., Zhang, X., Zaman, M., Chu, M., Wang, X., Yu, G., & Peng, J. (2025). Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021–2025). Molecular Neurodegeneration, 20, 83. DOI:10.1186/s13024-025-00874-5, https://link.springer.com/article/10.1186/s13024-025-00874-5
3. Wu, Q., Sui, X., & Tian, R. (2021). Advances in high-throughput proteomic analysis. Se Pu, 39(2), 112–117. DOI:10.3724/SP.J.1123.2020.08023, https://www.sciengine.com/doi/10.3724/SP.J.1123.2020.08023
4. Suhre, K., Venkataraman, G. R., Guturu, H., Halama, A., Stephan, N., Thareja, G., Sarwath, H., Motamedchaboki, K., Donovan, M. K. R., Siddiqui, A., Batzoglou, S., & Schmidt, F. (2024). Nanoparticle enrichment mass-spectrometry proteomics identifies protein-altering variants for precise pQTL mapping. Nature Communications, 15, 989. DOI:10.1038/s41467-024-45233-y, https://www.nature.com/articles/s41467-024-45233-y
5. Vitorino, R. (2024). Transforming Clinical Research: The power of High-Throughput Omics Integration. Proteomes, 12(3), 25. DOI:10.3390/proteomes12030025, https://www.mdpi.com/2227-7382/12/3/25
6. Chen, J., & Zheng, N. (2020). Accelerating protein biomarker discovery and translation from proteomics research for clinical utility. Bioanalysis, 12(20), 1469–1481. DOI:10.4155/bio-2020-0198, https://www.future-science.com/doi/10.4155/bio-2020-0198
7. Carrasco-Zanini, J., Pietzner, M., Davitte, J., Surendran, P., Croteau-Chonka, D. C., Robins, C., Torralbo, A., Tomlinson, C., Grünschläger, F., Fitzpatrick, N., Ytsma, C., Kanno, T., Gade, S., Freitag, D., Ziebell, F., Haas, S., Denaxas, S., Betts, J. C., Wareham, N. J., Hemingway, H., Scott, R. A., & Langenberg, C. (2024). Proteomic signatures improve risk prediction for common and rare diseases. Nature Medicine, 30(9), 2489–2498. DOI:10.1038/s41591-024-03142-z, https://www.nature.com/articles/s41591-024-03142-z
8. Song, J., Wang, C., Zhao, T., Zhang, Y., Xing, J., Zhao, X., Zhang, Y., & Zhang, Z. (2025). Multi-omics approaches for biomarker discovery and precision diagnosis of prediabetes. Frontiers in Endocrinology, 16, 1520436. DOI:10.3389/fendo.2025.1520436, https://www.frontiersin.org/articles/10.3389/fendo.2025.1520436/full
9. Ho, F. K., Mark, P. B., Lees, J. S., Pell, J. P., Strawbridge, R. J., Kimenai, D. M., Mills, N. L., Woodward, M., McMurray, J. J. V., Sattar, N., & Welsh, P. (2025). A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia. Circulation, 151(5), 277–287. DOI:10.1161/CIRCULATIONAHA.124.070454, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.070454
10. Xiang, S., Ye, Y., Cao, X., Zeng, H., Guan, Y., Zhu, S., Liu, X., Luo, D., Kong, Y., Shao, Z., Zhang, B., & Hao, X. (2026). Proteomic signatures and machine learning based-prediction models for cardiovascular risk in survivors of myocardial infarction. BMC Cardiovascular Disorders, 26(1), 121. DOI:10.1186/s12872-025-05487-w, https://link.springer.com/article/10.1186/s12872-025-05487-w
11. Gasparri, R., Noberini, R., Cuomo, A., Yadav, A., Tricarico, D., Salvetto, C., Maisonneuve, P., Caminiti, V., Sedda, G., Sabalic, A., Bonaldi, T., & Spaggiari, L. (2023). Serum proteomics profiling identifies a preliminary signature for the diagnosis of early-stage lung cancer. Proteomics Clinical Applications, 17(2), e2200093. DOI:10.1002/prca.202200093, https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/prca.202200093
12. Gong, K., Timsina, J., Ali, M., Chen, Y., Liu, M., Wang, C., Pottier, C., Feld, G. K., Heo, G., Benzinger, T. L. S., Raji, C. A., Ances, B., Gordon, B. A., Wisch, J. K., Schindler, S. E., Morris, J. C., Holtzman, D. M., Ibanez, L., & Cruchaga, C. (2025). High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed-dementia cohort. Molecular Neurodegeneration, 20, 120. DOI:10.1186/s13024-025-00909-x, https://link.springer.com/article/10.1186/s13024-025-00909-x
13. Li, Y., Li, D., Lin, J., Zhou, L., Yang, W., Yin, X., Xu, C., Cao, Z., & Wang, Y. (2025). Proteomic signatures of type 2 diabetes predict the incidence of coronary heart disease. Cardiovascular Diabetology, 24, 120. DOI:10.1186/s12933-025-02670-3, https://link.springer.com/article/10.1186/s12933-025-02670-3
14. Smith, A., Elliott, P., Mayr, M., Dehghan, A., & Tzoulaki, I. (2025). Proteomic risk scores for predicting common diseases using linear and neural network models in the UK biobank. Scientific Reports, 15, 20520. DOI:10.1038/s41598-025-06232-1, https://www.nature.com/articles/s41598-025-06232-1
15. Qiu, S., Hu, Y., Liu, J., & Wang, Y. (2025). Proformer: a multimodal proteomics transformer model for multidisease early risk assessment. Briefings in Bioinformatics, 26(6), bbaf686. DOI:10.1093/bib/bbaf686, https://academic.oup.com/bib/article/26/6/bbaf686/8405717
16. Korff, K., Müller-Reif, J. B., Fichtl, D., Albrecht, V., Schebesta, A.-S., Itang, E. C. M., Virreira Winter, S., Holdt, L. M., Teupser, D., Mann, M., & Geyer, P. E. (2025). Pre-analytical drivers of bias in bead-enriched plasma proteomics. EMBO Molecular Medicine, 17(11), 3174–3196. DOI:10.1038/s44321-025-00309-0, https://www.embopress.org/doi/10.1038/s44321-025-00309-0
17. Distler, U., Yoo, H. B., Kardell, O., Hein, D., Sielaff, M., Scherer, M., Jozefowicz, A. M., Leps, C., Gomez-Zepeda, D., von Toerne, C., Merl-Pham, J., Barth, T. K., Tüshaus, J., Giesbertz, P., Müller, T., Kliewer, G., Aljakouch, K., Helm, B., Unger, H., ...Tenzer, S. (2025). Multicenter evaluation of label-free quantification in human plasma on a high dynamic range benchmark set. Nature Communications, 16, 8774. DOI:10.1038/s41467-025-64501-z, https://www.nature.com/articles/s41467-025-64501-z
18. Mischak, H., Schanstra, J. P., Vlahou, A., & Beige, J. (2025). Clinical proteomics, quo vadis? Proteomics, 25(7), e202400346. DOI:10.1002/pmic.202400346, https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/pmic.202400346
19. Tang, J., Yue, L., Xu, Y., Xu, F., Cai, X, Fu, Y., Miao, Z., Gou, W., Hu, W., Xue, Z., Deng, K., Shen, L., Jiang, Z., Shuai, M., Liang, X., Xiao, C., Xie, Y., Guo, T., Chen, Y.-m., & Zheng, J.-S. (2025). Longitudinal serum proteome mapping reveals biomarkers for healthy ageing and related cardiometabolic diseases. Nature Metabolism, 7, 166–181. DOI:10.1038/s42255-024-01185-7, https://www.nature.com/articles/s42255-024-01185-7

Last Updated: Mar 9, 2026